buphenine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| analgesics, glafenine derivatives (subgroup of fenamic acid group) | 1976 | 447-41-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
| 30 | mg | P |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C04AA02 | CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS PERIPHERAL VASODILATORS 2-amino-1-phenylethanol derivatives |
| ATC | G02CA02 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Sympathomimetics, labour repressants |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D015149 | Tocolytic Agents |
| MeSH PA | D014665 | Vasodilator Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Disorder of blood vessel | indication | 27550009 | DOID:178 |
| Inner Ear Disturbance | indication | ||
| Tachyarrhythmia | contraindication | 6285003 | |
| Paroxysmal tachycardia | contraindication | 12026006 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Progressive Angina Pectoris | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.52 | acidic |
| pKa2 | 9.04 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Adrenergic receptor alpha-1 | GPCR | Kd | 6.21 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017871 | VUID |
| N0000179434 | NUI |
| D01543 | KEGG_DRUG |
| 849-55-8 | SECONDARY_CAS_RN |
| 4017871 | VANDF |
| 4019862 | VANDF |
| C0028735 | UMLSCUI |
| CHEBI:31925 | CHEBI |
| CHEMBL114655 | ChEMBL_ID |
| CHEMBL1204337 | ChEMBL_ID |
| DB06152 | DRUGBANK_ID |
| 4567 | PUBCHEM_CID |
| 7595 | RXNORM |
| 000699 | NDDF |
| 004516 | NDDF |
| 111140007 | SNOMEDCT_US |
| 44520000 | SNOMEDCT_US |
| D009756 | MESH_DESCRIPTOR_UI |
| 461 | INN_ID |
| EC69E3PW7E | UNII |
Pharmaceutical products:
None